Low pre-radiotherapy prostate-specific antigen level is a significant predictor of treatment success for postoperative radiotherapy in patients with prostate cancer

Anticancer Research

Volumn 26, Issue 3 B, 2006, Pages 2367-2374

  Sasaki, Tomonari ^a   Nakamura, Katsumasa ^b   Shioyama, Yoshiyuki ^b   Ohga, Saiji ^b   Toba, Takashi ^b   Urashima, Yusuke ^b   Yoshitake, Tadamasa ^b   Terashima, Hiromi ^c   Koga, Hirofumi ^b   Naito, Seiji ^b   Noma, Hideya ^d   Komatsu, Kiyoshi ^d   Yamaguchi, Akito ^d   Hiratsuka, Yoshiharu ^e   Hirano, Tomomi ^f   Hanada, Kiyohiko ^f   Abe, Madoka ^g   Fujisawa, Yasuhito ^h   Honda, Hiroshi ^b  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d HARASANSHIN HOSPITAL   (Japan)

^e Fukuoka University Chikushi Hospital   (Japan)

^f KYUSHU CENTRAL HOSPITAL   (Japan)

^g FUKUOKA HIGASHI MEDICAL CENTER   (Japan)

^h National Hospital Organization   (Japan)

Author keywords

Postoperative radiotherapy; Prostate cancer; Prostatic specific antigen

Indexed keywords

AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HORMONAL THERAPY; HUMAN; IRRADIATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SALVAGE THERAPY;

AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 33745561070     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Kuroishi T and Tajima K: Cancer mortality in Japan (1950-2000). In: Cancer Mortality and Morbidity Statistics: Japan and the World-2004. Tajima K, Kuroishi T and Oshima A (eds.). Japan Scientific Societies Press 1-93, 2004.
2. Arai Y, Saito S, Namiki S et al: Radical prostatectomy for localized prostate cancer. Nippon Rinsho 63: 261-266, 2005 (in Japanese).
3. Pound CR, Partin AW, Eisenberger MA et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591-1597, 1999.
4. Naito S: Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer. Jpn J Clin Oncol 55: 365-374, 2005.
5. Nakamura K, Teshima T, Imai A et al: Radical radiation therapy for prostate cancer in Japan: a patterns of care study report. Jpn Clin Oncol 33: 122-126, 2003.
6. Numata K, Azuma K, Hashine K et al: Predictor of response to salvage radiotherapy in patients with PSA recurrence after radical prostatectomy: the usefulness of PSA doubling time. Jpn J Clin Oncol 35: 256-259, 2005.
7. Egawa S, Ohori M, Iwamura M et al: Efficacy and limitations of delayed/salvage radiation therapy after radical prostatectomy. BJU Int 84: 815-820, 1999.
8. Terai A, Matsui Y, Yoshimura K et al: Salvage radiotherapy for biochemical recurrence after radical prostatectomy. BJU Int 96: 1009-1013, 2005.
9. Sasaki T, Nakamura K, Shioyama Y et al: Efficacy of modest dose irradiation in combination with long-term endocrinal treatment for high-risk prostate cancer: a preliminary report. Jpn J Clin Oncol 34: 420-424, 2004.
10. Anscher MS and Prosnitz LR: Postoperative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicle involvement and/or penetration through the capsule. J Urol 138: 1407-1412, 1987.
11. Schild SE, Wong WW, Grado GL et al: The result of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer. Int J Radiat Oncol Biol Phys 34: 535-541, 1996.
12. Valicenti RK, Gomella LG, Ismail M et al: The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys 45: 53-58, 1999.
13. Nudell DM, Grossfeld GD, Weinberg VK et al: Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns. Urology 54: 1049-1057, 1999.
14. Hagan M, Zlotecki R, Medina C et al: Comparison of adjuvant versus salvage radiotherapy policies for postprostatectomy radiotherapy. Int J Radiat Oncol Biol Phys 59: 329-340, 2004.
15. Bolla M, van Poppel H, Collette L et al: Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22911). Lancet 366: 572-578, 2005.
16. Epstein JI: Incidence and significance of positive margins in radical prostatectomy specimens. Urol Clin North Am 23: 651-663, 1996.
17. Schild SE: Radiation therapy after prostatectomy: now or later? Semin Radiat Oncol 8: 132-139, 1998.
18. Vargas C, Kestin LL, Weed DW et al: Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Int J Radiat Oncol Biol Phys 61: 714-724, 2005.
19. Connolly JA, Shinohara K, Presti JC Jr et al: Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 47: 225-231, 1996.
20. Perez CA, Michalski J, Brown KC et al: Nonrandomized evaluation of pelvic lymph node irradiation in localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 36: 573-578, 1996.
21. Seaward SA, Weinberg V, Lewis P et al: Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 42: 1055-1062, 1998.
22. Roach M 3rd, DeSilvio M, Lawton C et al: Radiation Therapy Oncology Group 9413. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21: 1904-1911, 2003.
23. Kim BS, Lashkari A, Vongtama R et al: Effect of pelvic lymph node irradiation in salvage therapy for patients with prostate cancer with a biochemical relapse following radical prostatectomy. Clin Prostate Cancer 3: 93-97, 2004.
24. Perez CA, Michalski JM, Baglan K et al: Radiation therapy for increasing prostate-specific antigen levels after radical prostatectomy. Clin Prostate Cancer 1: 235-241, 2003.
25. Levesque PE, Nieh PT, Zinman LN et al: Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy. Urology 51: 978-984, 1998.
26. Valicenti RK, Gomella LG and Perez CA: Radiation therapy after radical prostatectomy: a review of the issues and options. Semin Radiat Oncol 13: 130-140, 2003.
27. Cox JD, Gallagher MJ, Hammond EH et al: Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 17: 1155-1163, 1999.
28. Zelefsky MJ, Aschkenasy E, Kelsen S et al: Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 39: 327-323, 1997.
29. Pollack A, Smith LG and von Eschenbach AC: External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys 48: 507-512, 2000.
30. Eulau SM, Tate DJ, Stamey TA et al: Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer. Int J Radiat Oncol Biol Phys 41: 735-740, 1998.